These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9132622)

  • 1. [Predictive factors for therapeutic success in depressive syndrome].
    Faltermaier-Temizel M; Laakmann G; Baghai T; Kuhn K
    Nervenarzt; 1997 Jan; 68(1):62-6. PubMed ID: 9132622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.
    Peet M; Horrobin DF
    Arch Gen Psychiatry; 2002 Oct; 59(10):913-9. PubMed ID: 12365878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical differences between early and late remission in depressive patients.
    Roca M; García-Toro M; García-Campayo J; Vives M; Armengol S; García-García M; Asensio D; Gili M
    J Affect Disord; 2011 Nov; 134(1-3):235-41. PubMed ID: 21676465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variables influencing antidepressant medication adherence for treating outpatients with depressive disorders.
    Lee MS; Lee HY; Kang SG; Yang J; Ahn H; Rhee M; Ko YH; Joe SH; Jung IK; Kim SH
    J Affect Disord; 2010 Jun; 123(1-3):216-21. PubMed ID: 19914719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
    Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
    J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of (non-) response in depressed outpatients treated with a three-phase sequential medication strategy.
    Hoencamp E; Haffmans PM; Duivenvoorden H; Knegtering H; Dijken WA
    J Affect Disord; 1994 Aug; 31(4):235-46. PubMed ID: 7989638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which depressions respond to placebo?
    Fairchild CJ; Rush AJ; Vasavada N; Giles DE; Khatami M
    Psychiatry Res; 1986 Jul; 18(3):217-26. PubMed ID: 3529150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.
    Khan A; Schwartz K; Kolts RL; Ridgway D; Lineberry C
    Biol Psychiatry; 2007 Jul; 62(1):65-71. PubMed ID: 17141744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Practical modalities of consolidation treatment].
    Dalery J; Sechter D
    Encephale; 1995 Mar; 21 Spec No 2():43-5. PubMed ID: 7588179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of antidepressant response.
    Goodwin FK
    Bull Menninger Clin; 1993; 57(2):146-60. PubMed ID: 8508153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study.
    Grassi L; Biancosino B; Marmai L; Righi R
    J Clin Psychiatry; 2004 Apr; 65(4):515-20. PubMed ID: 15119914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report.
    Nierenberg AA; Fava M; Trivedi MH; Wisniewski SR; Thase ME; McGrath PJ; Alpert JE; Warden D; Luther JF; Niederehe G; Lebowitz B; Shores-Wilson K; Rush AJ
    Am J Psychiatry; 2006 Sep; 163(9):1519-30; quiz 1665. PubMed ID: 16946176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients.
    Mendels J; Reimherr F; Marcus RN; Roberts DL; Francis RJ; Anton SF
    J Clin Psychiatry; 1995; 56 Suppl 6():30-6. PubMed ID: 7649971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tridimensional personality questionnaire as a predictor of response to nefazodone treatment of depression.
    Nelson EC; Cloninger CR
    J Affect Disord; 1995 Oct; 35(1-2):51-7. PubMed ID: 8557887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nefazodone and imipramine in major depression: a placebo-controlled trial.
    Rickels K; Schweizer E; Clary C; Fox I; Weise C
    Br J Psychiatry; 1994 Jun; 164(6):802-5. PubMed ID: 7952987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients.
    Szegedi A; Jansen WT; van Willigenburg AP; van der Meulen E; Stassen HH; Thase ME
    J Clin Psychiatry; 2009 Mar; 70(3):344-53. PubMed ID: 19254516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gradual discontinuation of lithium augmentation in elderly patients with unipolar depression.
    Hardy BG; Shulman KI; Zucchero C
    J Clin Psychopharmacol; 1997 Feb; 17(1):22-6. PubMed ID: 9004053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.